Status:
COMPLETED
Remote Ischemic Preconditioning for Renal Protection in TAVI
Lead Sponsor:
Henry Ford Health System
Conditions:
Aortic Valve Stenosis
Renal Insufficiency
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Severe aortic stenosis remains a major cause of morbidity and mortality of the elderly affecting approximately 3% of elderly patients with an increasing number of patients undergoing transcatheter aor...
Eligibility Criteria
Inclusion
- \- Adults aged 18 or older presenting with moderate to severe aortic stenosis for a trans-catheter aortic valve intervention
Exclusion
- Patients in cardiogenic shock defined as requiring circulatory or hemodynamic support with a device, vasopressors or inotropes
- Systemic hypotension (systolic blood pressure \< 90mmHg)
- Patients currently on hemodialysis
- Presence of an arteriovenous dialysis fistula or graft or lymphedema in either arm
- Patients enrolled in other active cardiovascular investigational studies
- Severe comorbidities with a life expectancy of less than 6 months
- Pregnant or lactating women
- Patients unable to provide consent
- Patients taking the medication glibenclamide for treatment of diabetes
Key Trial Info
Start Date :
February 13 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2018
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT03347032
Start Date
February 13 2018
End Date
December 30 2018
Last Update
December 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Hospital
Detroit, Michigan, United States, 48202